Novogen Limited, a pharmaceutical company, engages in the discovery, development, manufacture, and marketing of products based on isoflavoniod technology. Its products development program comprises a range of pharmaceuticals based on phenolic compounds in humans, and dietary supplements based on plant compounds known as isoflavones. The company's products include dietary supplements, such as Promensil, Trinovin, and Rimostil for people whose intake of isoflavones is inadequate. Novogen also develops transNV-04, a cardiovascular drug, which is in phase Ib human clinical trial; NV-52, an anti-inflammatory drug, which is in phase I human clinical trials for inflammatory bowel disease; and phenoxodiol, an anti-cancer drug for the treatment of prostate cancer, ovarian cancer, and squamous cell carcinomas. In addition, the company, through its subsidiary, conducts clinical trials, commercializes, and distributes the anti-cancer drug candidates, NV-196, which is in Phase I human testing in Australia and is being developed initially in oral form for the treatment of pancreatic and bile duct cancers; and NV-143, which is in pre-clinical testing for treating melanoma, glioma, prostate, ovarian, breast, and lung cancer. Novogen sells its products through its distributors and other third parties in Australia, New Zealand, the United States, Canada, Singapore, South Africa, Austria, Ireland, Italy, and various other European countries. The company was incorporated in 1994 and is headquartered in North Ryde, Australia.